Once again AstraZeneca has been recognised as one of the leading companies in the Pharmaceuticals industry by the Dow Jones Sustainability Indices (DJSI Europe and DJSI World).
DJSI is the longest-standing, global sustainability benchmark system, based on an in-depth analysis of companies’ economic, social and environmental performance. The company maintained their 2018 overall score and achieved a perfect score of 100 in the categories of Environmental Reporting, Labour Practice Indicators, Social Reporting and Health Outcome Contribution.
AstraZeneca has also again been named as a member of the FTSE4Good Index Series, demonstrating the company’s strong environmental, social and governance (ESG) practises.
While expert third party analysis and recognition of sustainability performance is valuable, AstraZeneca’s ambition is to build transparency as a foundation of trust with all stakeholders including investors, employees, patients, partners, healthcare professionals, governments and society.
The company is therefore aiming to make the same information accessible to everyone and has launched a new interactive Transparency Map as the latest step to achieving that ambition. Search by country to explore the sourcing and manufacturing activities involved in delivering medicines to patients, as well as information on Access to Healthcare programmes, and intellectual property and healthcare professional payment disclosure practices around the world.
Maintaining a leading position in these important indices is the result of our continuing efforts to make progress against our focus area targets and to embed sustainability into the way we work. Our commitment to transparency reflects our belief that we build trust by demonstrating ethical business practices and being transparent in everything we do, recognising increasing stakeholder expectations.